Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Navigated Focused Ultrasound in Recurrent Glioblastoma
NCT07385846Phase 1Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in glioblastoma (GBM). Primary endpoints: Safety of using navigated focused ultrasound (NaviFUS) at 2 years and Feasibility of using navigated focused ultrasound (NaviFUS) at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07385846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385846.